AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage ...

AstraZeneca posted higher profit in the first quarter, driven by sales of its diabetes and cancer medicines. The British ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

AstraZeneca (AZN) halts Truqap trial for prostate cancer after an independent review finds it unlikely to meet survival or ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

The drug maker said it is ‘firmly committed to investing and growing in the US’ amid potential import tariffs on the ...

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

China: In relation to the illegal drug importation allegations, AstraZeneca received an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...